Ownership and insider activity for Neurogene Inc. (NGNE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Price
| Price | $34.67 |
| Market Cap | $548M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-06 | Cvijic Christine Mikail | S-Sale | 600 | $22K |
| 2026-07-07 | Cvijic Christine Mikail | S-Sale | 4,200 | $152K |
| 2026-07-01 | Cvijic Christine Mikail | S-Sale | 739 | $25K |
| 2026-07-02 | Cvijic Christine Mikail | S-Sale | 2,531 | $88K |
| 2026-07-02 | Cvijic Christine Mikail | S-Sale | 1,530 | $54K |
| 2024-01-16 | Woods Keith | A-Award | 15,400 | $497K |
| 2024-06-14 | Woods Keith | A-Award | 7,700 | $328K |
| 2025-06-12 | Woods Keith | A-Award | 12,050 | $246K |
| 2023-12-18 | Woods Keith | |||
| 2026-05-06 | Cvijic Christine Mikail | S-Sale | 4,800 | $144K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.3M | $52.0M | $76.9M | $143.1M | $192.6M | $70.5M | $82.0M | $148.2M | $136.6M | $103.8M |
| Short-term Investments | $70.8M | $56.1M | 0 | 0 | 0 | 0 | 0 | $48.9M | $175.8M | $165.2M |
| Receivables | 0 | 0 | 0 | 0 | 0 | $790000 | 0 | $600000 | $648000 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | $1.9M | 0 | 0 | 0 | 0 |
| Total Current Assets | $103.5M | $108.8M | $77.2M | $143.6M | $194.5M | $74.0M | $84.7M | $200.3M | $315.9M | $271.8M |
| Property, Plant & Equipment | $849000 | $905000 | $400000 | $2.8M | $13.7M | $27.5M | $24.5M | $21.0M | $18.5M | $15.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $567000 | $347000 | $128000 | 0 | 0 | 0 | 0 |
| Total Assets | $154.4M | $110.3M | $77.6M | $147.0M | $210.5M | $101.5M | $109.3M | $222.6M | $335.7M | $288.6M |
| Accounts Payable | 0 | 0 | $702000 | $1.6M | $1.3M | $5.6M | $625000 | $2.6M | $1.3M | $2.0M |
| Short-term Debt | 0 | 0 | 0 | $618000 | $708000 | $1.2M | 0 | 0 | $3.0M | $3.1M |
| Total Current Liabilities | $9.5M | $11.0M | $4.6M | $4.7M | $7.9M | $10.9M | $6.7M | $23.0M | $15.2M | $16.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $6.8M |
| Total Liabilities | $9.7M | $11.4M | $4.9M | $5.3M | $19.3M | $193.4M | $10.6M | $36.5M | $25.4M | $23.7M |
| Retained Earnings | -$148.3M | -$198.5M | -$230.1M | -$299.5M | -$332.8M | -$95.6M | -$150.8M | -$187.2M | -$262.3M | -$352.6M |
| Total Equity | $144.7M | $98.9M | $72.7M | $141.7M | $191.2M | -$91.9M | $98.6M | $186.0M | $310.4M | $264.9M |
| Total Debt | $47000 | $32999 | $6000 | $1.2M | $12.1M | $6.4M | $4.7M | $16.3M | $12.4M | $9.9M |
| Net Debt | -$103.0M | -$108.1M | -$76.9M | -$141.9M | -$180.4M | -$64.1M | -$77.3M | -$180.9M | -$300.0M | -$259.1M |
| Working Capital | $94.0M | $97.9M | $72.5M | $138.9M | $186.6M | $63.1M | $78.1M | $177.4M | $300.8M | $255.4M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 10.64 |
Profitability
| Return on Equity | -45.11% |
| Return on Invested Capital | -53.72% |
| Return on Assets | -45.47% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADCT · ALMS · AUTL · BNTC · FULC · LCTX · OCGN
Explore sector: Healthcare · Biotechnology
More sections of NGNE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks